Introduction {#s1}
============

Schistosomiasis (infection with parasitic blood flukes) affects over 230 million people, with severe infections causing \~200,000 deaths per year. Chronic infections are associated with morbidities such as anemia, impaired cognitive development and stunted growth ([@bib13]; [@bib32]). Infection is acquired upon exposure to freshwater, larval cercariae which penetrate the host skin. Inside host tissue, cercariae transform into schistosomula that access and traverse the circulatory system, pass through the lungs and liver before finally residing as mature adults within either the mesenteric vessels (*Schistosoma mansoni* and *Schistosoma japonicum*) or vasculature surrounding the urinary bladder (*Schistosoma haematobium*) ([@bib58]; [@bib24]). The sexually mature male and female worms pair up and generate a prodigious number of eggs, depositing hundreds to thousands of eggs per female worm per day ([@bib12]; [@bib11]; [@bib3]). Eggs lodge within the peritoneal organs, evoking a massive Th2 response which cues granuloma formation and consequent pathology in affected organs (reviewed in \[[@bib12]\]). In the case of urogenital schistosomiasis (*S. haematobium* infection) eggs are deposited in the bladder mucosa and urinary tract, resulting in hematuria and increased rates of squamous-cell carcinoma. In the case of intestinal schistosomiasis (*S. mansoni* and *S. japonicum* infections), eggs are deposited in the liver and hepatic portal system leading to periportal fibrosis, pulmonary hypertension and ascites.

Broad spectrum chemotherapy of schistosomiasis relies upon praziquantel (PZQ), which has been in clinical use for nearly 40 years ([@bib13]; [@bib32]; [@bib2]). Mass drug administration (MDA) programs will require \~250 million tablets of PZQ per year for at risk populations ([@bib44]). The widespread distribution of schistosomiasis, coupled with observations that PZQ can be subcurative in areas of high intensity of infection and transmission ([@bib14]; [@bib33]) raise concerns that treatment resistant parasites may emerge ([@bib19]; [@bib20]; [@bib30]; [@bib56]). Therefore, it is important to identify new flatworm drug targets and lead compounds to expand the arsenal of drugs available to treat schistosomiasis and other parasitic flatworm infections currently resolved through PZQ administration.

In this regard, targeting parasite neuromuscular physiology has proven to be a highly successful anthelmintic approach ([@bib23]). In schistosomes, serotonin (5-HT) controls motor function and a specific serotonergic G-protein coupled receptor (GPCR) mediating this effect has been implicated by both RNAi ([@bib45]) and drug screening ([@bib10], [@bib7]). Here, we cloned full-length 5-HT receptor sequences from each of three major species causing human infection worldwide and expressed these targets in a high-throughput capable assay enabling screening of thousands of compounds from natural product libraries. The dataset identified anti-schistosomal chemotypes that conveyed anti-parasitic efficacy. Most importantly these activities led to the discovery that the ergot alkaloid ergotamine ameliorated both infection and the pathological sequelae of infection. These properties highlight an opportunity to combat schistosome infections and their pathological impact on the host using single agents that coalesce deleterious actions on parasites with beneficial activities on host responses.

Results {#s2}
=======

Pharmacological profiling of a schistosome 5-HTR {#s2-1}
------------------------------------------------

Full-length sequences for a serotoninergic GPCR (5-HTR) were cloned from the three major schistosome species causing infections worldwide; *Schistosoma mansoni* (Sm.5HTR~L~\[[@bib7]\]), *S. haematobium* (Sh.5HTR) and *S. japonicum* (Sj.5HTR). The three 5HTRs shared high amino acid similarity (84--94%), and clustered with 5-HT~7~ receptors from other organisms ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}). In mammalian HEK293 cells, GFP-tagged variants of each 5-HTR localized at the cell surface ([Figure 1A](#fig1){ref-type="fig"}), enabling functional profiling. To measure signaling output, GPCR activity was assessed using a luciferase based cAMP reporter (GloSensor 22F, Promega) engineered to undergo a conformational change on cAMP binding that increases luciferase activity ([Figure 1B](#fig1){ref-type="fig"}). The choice of this reporter was guided by prior evidence demonstrating coupling of the flatworm SER-7 GPCRs to G~s~ ([@bib45]; [@bib7], [@bib17]) and the ability of this approach to resolve real time kinetics of cAMP generation with high sensitivity in intact cells. The 5-HTRs from each individual schistosome species were transiently transfected into a stable HEK293 cell line expressing the cAMP reporter and luminescence values monitored during addition of 5-HT. Each of the GPCRs responded to the addition of 5-HT with a rapid elevation in luminescence values (\~70--110 fold increase, [Figure 1C](#fig1){ref-type="fig"}) with sensitivity in the low nanomolar range for Sj.5HTR and Sh.5HTR (EC~50~ = 3.0 ± 0.3, 3.6 ± 0.3 nM) and 76 ± 1 nM for Sm.5HTR~L~ ([Figure 1D](#fig1){ref-type="fig"}). To facilitate high-throughput drug screening of these targets, dual stable cell lines expressing both the cAMP reporter and individual 5-HTR clones were derived and individual lines evaluated based on performance in a 384-well format. Conditions were iterated to deliver robust resolution of the signals elicited by 5-HT ('agonist screen', Z' score \>0.7, signal window \>10) and the known inhibitory action of bromocriptine ('antagonist screen', Z' score \>0.6, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), a previously identified antagonist ([@bib7]).

![Functional expression of *Schistosoma* serotonin receptors.\
(**A**) Confocal images showing cell surface expression in mammalian HEK293 cells of 5-HT receptors cloned from *S. mansoni* (*Sm*.5HTR~L~), *S. haematobium* (*Sh.*5HTR) and *S. japonicum* (*Sj*.5HTR) localized by COOH-terminally tagged eGFP. Scalebar, 50 µm. (**B**) Schematic of luminescent cAMP sensor bioassay. cAMP generated by schistosome 5-HTRs (blue) binds the engineered GloSensor luciferase, switching the sensor to a more active conformation resulting in enhanced luminescence output. (**C**) Kinetics of signal following the addition of 5-HT (1 µM) to HEK293 cells co-transfected with luminescent cAMP sensor and individual schistosome 5-HT receptors. Open circles, cells not transfected with 5-HT receptor, colored circles represent measurements in cells transfected with *Sm*.5HTR~L~ (black), (*Sh.*5HTR (blue) and *Sj*.5HTR (red). (**D**) Serotonin dose-response curves for each of the three receptors (colored circles) and HEK293 cells expressing the cAMP sensor alone (open circles). Data reflect mean ± standard error of at least 3 biological replicates.](elife-35755-fig1){#fig1}

Having optimized these methods, we proceeded to screen the *S. mansoni* 5HTR~L~ against a compilation of natural product libraries (4288 compounds, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). The screening protocol consisted of an 'agonist screen' (addition of compound alone, 10 µM) followed by an 'antagonist screen' (inhibition of response to 5-HT, 1 µM) in the same cells for every compound. The workflow, and criteria for putative 'hit' designation, from the primary screen are shown in [Figure 2A](#fig2){ref-type="fig"}. An example of the data profile generated for a putative agonist 'hit' and an antagonist 'hit' is shown in [Figure 2B](#fig2){ref-type="fig"}.

![High-throughput screen of natural product libraries against *Sm*.5HTR~L~.\
(**A**) Assay workflow for drug screen. Compounds were screened against HEK293 cells stably expressing a cAMP sensor and *Sm*.5HTR~L~, followed by counter-screening hits against a cell line lacking *Sm*.5HTR~L~. (**B**) Kinetic readout of luminescence from cAMP biosensor following addition of (i) test compound (10 µM, open arrow; agonist hits increase luminescence), followed by (ii) the addition of 5-HT (1 µM, solid arrow; antagonist hits decrease luminescence relative to controls). (**C**) Scatter plot of compounds assaying for (i) agonists and (ii) antagonists. Putative hits surpassing threshold are shown in color (blue, agonists; red, antagonists). (**D**) Counter-screen of putative hit compounds from (**C**) against cell lines lacking 5-HT receptor to exclude compounds with off-target increases in cAMP (top) or compounds that reduce forskolin (25 µM) evoked cAMP signals (bottom). (**E**) Hits clustered into compound classes by structure. Groups contain common ring systems such as benzylisoquinoline (ex. 1. ST059293, 2. Nantenine, 3. 785163, 4. Nuciferine, 5. Remerine) or indole (6. Ergotamine, 7. Metergoline, 8. Nicergoline, 9. N-methylserotonin, 10. 5-bromotryptamine) structures. Blue = agonists, red = antagonists.](elife-35755-fig2){#fig2}

Compilation of the screening dataset is shown in [Figure 2C](#fig2){ref-type="fig"}, where the fold-increase ('agonist screen') or decrease (relative to 5-HT, 'antagonist screen') in luminescence values are plotted for individual compounds. From the whole dataset (4288 ligands), 92 putative hits were identified that exceeded threshold criteria ([Figure 2C](#fig2){ref-type="fig"}). These compounds were then counter-screened against the parental HEK293 reporter cell line lacking any schistosome 5-HTR ([Figure 2D](#fig2){ref-type="fig"}). This was necessary to exclude false positive hits, for example compounds that stimulated cAMP production through endogenous HEK293 targets (GPCRs, direct adenylate cyclase activators), or compounds that non-specifically inhibited cAMP production. Counter-screening triaged 40 of the original 92 hits, invalidating compounds that either stimulated cAMP production or inhibited forskolin-evoked cAMP generation in cells lacking Sm.5HTR~L~. Overall, the screening dataset yielded 52 compounds (12 agonists and 40 antagonists at Sm.5HTR~L~, \~1.2% hit rate) for subsequent investigation. Chemotype analysis of the 'hit' compounds ([Figure 2E](#fig2){ref-type="fig"}) revealed two main groups of favored structures. The first core group of ligands were benzylisoquinolines with aporphine or protoberberine cores. These compounds were exclusively antagonists. The second group of compounds contained an indole ring system, either bicyclic tryptamines, or ergot alkaloids with a four ring ergoline core. This second group of compounds comprised both agonist and antagonist ligands. This range of efficacies underpinned prioritization of these ligands, and ergot alkaloids as the predominant chemotype, for further analysis of the structure-activity relationship at the parasitic 5-HTRs.

Structural determinates of activity at schistosome 5-HTRs {#s2-2}
---------------------------------------------------------

Ergot alkaloids are a diverse group of compounds with a long history of therapeutic use. Their interaction with mammalian bioaminergic GPCRs encompasses a range of activities and kinetic profiles ([@bib34]; [@bib55]). Based on the results from the natural product screen, an expanded series of ergot alkaloid ligands was sourced for structure-activity screening ('SAR by commerce'). Complete dose-response relationships were performed for twenty compounds containing the tetracyclic ergoline skeleton (5 compounds from the primary screen plus 15 commercially sourced ligands) against all three schistosome 5.HTRs (Sm.5HTR~L~, Sh.5HTR and Sj.5HTR).

Ergot alkaloid interactions with the schistosome 5-HTRs spanned a range of effects. To summarize these actions, agonist efficacy (relative to peak levels of 5-HT evoked cAMP generation) and antagonist potency (pKi) were represented as heat-maps where increasingly intense coloration represents higher efficacy ([Figure 3A](#fig3){ref-type="fig"}) and potency ([Figure 3B](#fig3){ref-type="fig"}). Several features of this dataset merit comment. First, these representations convey a shared responsiveness across the three 5-HTRs to tested ligands, suggesting a conservation of pharmacological profile between the 5-HTR orthologs from the different schistosome species. This is important if any putative lead compounds are to be broad spectrum, that is effective against each of the major infective strains. Second, the data evidence a broad spectrum of potencies and efficacies within the ergot alkaloid series evidencing full agonists (for example, compound '1' ergotamine, '2' dihydroergotamine), partial agonists (compound '3', lisuride), antagonists (compounds '16' terguride, '19', bromocriptine, '20' 2-bromo-LSD) as well as closely related 'inactive' compounds (compound '14', α-ergocryptine). Third, marked changes in efficacy and inhibitory potency resulted from minimal structural modifications to the core scaffold. For example, hydrogenation of the D9-10 double bond of lisuride (compound '3') eliminated efficacy to yield the antagonist terguride (compound '16', IC~50~ = 400 ± 50 nM, [Figure 3C](#fig3){ref-type="fig"}). The partial agonist LSD (compound '6') is converted into a potent antagonist (IC~50~ = 100 ± 20 nM) on bromination at the B2 indol ring position (2-Bromo-LSD, compound '20'). Distinct structural modifications impacting efficacy could be seen in an ergopeptine series ([Figure 3D](#fig3){ref-type="fig"}), through comparison of the chemical structures of ergotamine (compound '1'), a potent full agonist at each schistosome receptor (E~max~95 ± 4, 96 ± 5 and 114 ± 3% of 5-HT for Sm.5HTR~L~, Sh.5HTR and Sj.5HTR, respectively), the inactive α-ergocryptine (compound '14') and bromocriptine (compound' 19) which acted as a potent blocker (IC~50~ = 1.6 ± 0.4 µM) of Sm.5HTR~L~ ([Figure 3D](#fig3){ref-type="fig"}). Such SAR data underscore the potential for modifying the ergoline scaffold to maximize, or engineer away, efficacy at schistosome 5HTRs ([Figure 3C and D](#fig3){ref-type="fig"}).

![Structure activity relationship of ergot alkaloid compounds.\
Ergot alkaloids display a spectrum of activity against *Schistosoma* 5-HT receptors ranging from (**A**) agonists (expressed as maximal cAMP response relative to 5-HT) to (**B**) antagonists (estimated receptor affinity expressed as pKi). (**C**) Structure activity relationship within a lysergic acid amide series. Derivatives of the partial agonist LSD displayed modified activity following modification of the diethylamide moieties ([@bib14]; [@bib19]; [@bib12]; [@bib58]) or the ergoline ring system ([@bib23]; [@bib17]). (**D**) Structure activity relationship within a ergopeptine chemical series. Derivatives of the full agonist ergotamine with altered activity following modification of the tripeptide structure ([@bib3]; [@bib2]; [@bib30]) or the ergoline ring system ([@bib7]). Compound numbering reflects rank order of efficacy across the schistosome 5-HTRs: 1. Ergotamine; 2. Dihydroergotamine; 3. Lisuride; 4. 6-NOR LSD; 5. Methylergometrine; 6. LSD; 7. Dihydroergocristine; 8. Dihydroergotoxine; 9. Pergolide; 10. LAMPA; 11. Elmoclavine; 12. Ergonovine; 13. Nicergoline; 14. α-ergocryptine; 15. Mesulergine; 16. Terguride; 17. LY215840; 18. Metergoline; 19. Bromocriptine; 20. BOL-148. Data represent mean ± standard error of at least three biological replicates.](elife-35755-fig3){#fig3}

Overall, structure-activity analysis across the three schistosome 5-HTRs identified ergotamine (compound '1) as the most potent, full agonist and 2-Bromo-LSD (compound '20') as the most potent antagonist for further evaluation.

Validation of Sm.5HTR~L~ ligands on schistosomes ex vivo {#s2-3}
--------------------------------------------------------

The effects of prioritized compounds from the screen were examined on the movement of adult parasites cultured ex vivo. Male and female worms respond to 5-HT with increased movement ([Figure 4A](#fig4){ref-type="fig"}). This responsiveness permits the basic screening assay shown in [Figure 4B](#fig4){ref-type="fig"}, where changes in worm motility are resolved in response to compound addition, and in the presence of 5-HT. For example, 5-HT (200 µM) increased worm movement, and 5-HT stimulation was not observed following preincubation with bromocriptine (1 µM, [Figure 4B](#fig4){ref-type="fig"}). Compounds that exhibited agonist activity at each of the three 5-HTRs in vitro also stimulated worm movement ex vivo ([Figure 4C](#fig4){ref-type="fig"}). While the rank order of potency varied slightly from the in vitro screen, an increase in potency of ergot alkaloids relative to 5-HT was evident (EC~50~ for 5-HT = 51.6 ± 3.0 µM, EC~50~ = 97.8 ± 31.6 nM for ergotamine, EC~50~ = 1.4 ± 0.5 µM for LSD). As expected, the potent antagonist BOL-148 ([Figure 3C](#fig3){ref-type="fig"}) blocked 5-HT evoked hyperactivity ([Figure 4D](#fig4){ref-type="fig"}). BOL-148 displayed \~10 fold higher potency than bromocriptine consistent with the results from the in vitro screen (IC~50~ = 28.8 ± 23.1 nM for BOL-148 versus IC~50~ = 331 ± 271 nM for bromocriptine, [Figure 4D](#fig4){ref-type="fig"}).

![Ergot alkaloid action against adult *S. mansoni* parasites ex vivo.\
(**A**) Serotonin induced increase in movement of *S. mansoni* adult male (M, solid circles) and female (F, open circles) parasites. (**B**) Adult *S. mansoni* movement in the absence of drug (black trace), following 5-HT addition (200 µM, blue), or exposure to a *Sm*.5HTR~L~ antagonist (BOL-148, 1 µM) and subsequent 5-HT (200 µM, red) addition. (**C**) Dose-response curves for *Sm*.5HTR~L~ agonist evoked stimulation of adult schistosome movement. Ergot alkaloids = solid symbols, 5-HT = open blue circles. (**D**) Dose-response curves for *Sm*.5HTR~L~ antagonist inhibition of 5-HT (200 µM) evoked movement. Worm movement data (**A, C--D**) reflect mean ± standard error of the mean for at least 3 biological replicates.](elife-35755-fig4){#fig4}

Antischistosomal action of Sm.5HTR~L~ ligands in vivo {#s2-4}
-----------------------------------------------------

Do these schistosome 5-HTR ligands display anthelmintic activity in vivo? As processes such as parasite feeding, mate pairing and movement within the host vasculature depend upon coordinated neuromuscular function, exposure to ligands that stimulate hyperactivity (5-HTR agonists) or cause paralysis (5-HTR antagonists) may promote dysfunction and parasite clearance.

One indicator of acute drug efficacy that may prove indicative of anthelmintic activity is a shift in location of the parasites from the mesenteric vessels to the liver (the 'hepatic shift'), where worms are subsequently targeted for elimination by the host immune system ([@bib5]; [@bib48]; [@bib41]). To examine the ability of the prioritized 5-HT ligands to cause this hepatic shift, mice harboring a mature schistosome infection (42 days p.i.) were given 5-HTR ligands by intraperitoneal injection and sacrificed three hours later to assess parasite distribution ([Figure 5A](#fig5){ref-type="fig"}). Numbers of worms residing within the mesenteries, portal vein or liver were assessed. Following treatment with PZQ (100 mg/kg), most of the worms were found within the liver (68.8 ± 14.1% of recovered parasites, [Figure 5B](#fig5){ref-type="fig"}), whereas worms were infrequently found within the liver in mice injected with vehicle control (9.7 ± 8.5% of recovered parasites). The performance of a selection of 5-HTR agonists or antagonists was then benchmarked relative to these standards.

![Ergot alkaloid agonists evoke an acute hepatic shift of parasites in vivo.\
(**A**) Location of mouse vasculature dissected after drug treatment to resolve worm location. Adult parasites normally reside in the mesenteric vasculature (i), but following anthelmintic treatment shift to the portal vein (ii) and liver (iii). (**B**) Left, quantification of percent worm burden found in either the mesenteries, portal vein or liver following treatment with DMSO (negative control), praziquantel (100 mg/kg, positive control) and various ergot alkaloid compounds. Diameter of circle represents proportionality of distribution. Right, bar chart represents efficacy of the same series of compounds at *Sm*.5HTR~L~.](elife-35755-fig5){#fig5}

Treatment with 5-HTR agonists elicited a hepatic shift ([Figure 5B](#fig5){ref-type="fig"}). However, treatment with 5-HTR antagonists did not alter worm distribution ([Figure 5B](#fig5){ref-type="fig"}). Furthermore, the extent of the hepatic shift observed in mice treated with 5-HTR agonists correlated with the measured efficacy of these agonists at the parasite 5.HTR ([Figure 5B](#fig5){ref-type="fig"}). Full agonists promoted the greatest shift: for example, ergotamine treatment of mice yielded a similar percentage of worms in the liver (75.1 ± 16.9%) as seen in mice treated with PZQ. Partial agonists promoted a lesser response, and 5-HTR antagonists were ineffective. For example, neither bromocriptine (2.0 ± 2.8% of worms in liver) or BOL-148 (5.2 ± 2.3% of worms in liver) caused a hepatic shift of worms ([Figure 5B](#fig5){ref-type="fig"}) despite the effectiveness of these compounds at arresting worm movement ex vivo ([Figure 4D](#fig4){ref-type="fig"}). Based on these data, we prioritized treatment of infected mice with ergotamine to assess amelioration of chronic schistosomiasis.

In vivo efficacy of ergotamine {#s2-5}
------------------------------

Mice were injected with vehicle control (DMSO), PZQ (50 mg/kg) or ergotamine (60 mg/kg) twice daily for one week starting 42 days post infection (p.i.). Control animals succumbed to infection (\~8--10 weeks p.i.) over a timeframe consistent with the onset of egg laying by sexually mature parasites as expected ([Figure 6A](#fig6){ref-type="fig"}, \[[@bib12]\]). By 15 weeks p.i., the majority of control mice were dead. Death rates were significantly reduced in ergotamine-treated mice (16.5% versus 68.9% mortality in control cohort, log-rank test p\<0.001, hazard ratio 5.02). PZQ-treated mice survived through 15 weeks with no observed lethality ([Figure 6A](#fig6){ref-type="fig"}).

![Ergotamine resolves infections and mitigates pathology of schistosomiasis in vivo.\
(**A**) Survival of mice infected with *S. mansoni* and treated for one week (days 42--49 post infection) with either vehicle control (DMSO. n = 26 mice), ergotamine (ERG, 60 mg/kg twice daily. n = 22 mice) or praziquantel (PZQ, 50 mg/kg daily. n = 10 mice). (**B**) Worm burden of mice treated as in A and sacrificed 49 days post-infection. (**C**) Intestinal egg counts of mice sacrificed in B. (**D**) Representative livers and spleens from uninfected mice and infected mice exposed to vehicle (DMSO), ergotamine (ERG) or praziquantel (PZQ). Quantification of hepatomegaly (**E**) and splenomegaly (**F**) in uninfected mice (open columns) and infected mice following drug treatment (solid columns). (**G**) Histology of liver sections control uninfected and infected (DMSO) mice, as well as drug treated (ERG and PZQ) infected animals (scale = 1 mm). Liver histology using (I) H and E staining, (II) Movat's stain (collagen, yellow), (III) Masson's trichrome stain (collagen, blue), (IV) aldehyde fuchsin stain (elastin, purple), (V) Oil red O stain (lipid, red), and (VI) caspase-3 activation (brown puncta, arrows). Higher magnification images of egg granulomas for each staining condition are shown in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}.](elife-35755-fig6){#fig6}

As ergotamine increased survival of infected mice, we assessed various metrics of infection (worm burden, egg number, hepatosplenomegaly) immediately following ergotamine treatment (42--49 days p.i). First, ergotamine treatment significantly reduced worm burden from 28 ± 8 worm pairs per mouse to 9 ± 6 worm pairs per mouse (\~65% reduction, p\<0.002; [Figure 6B](#fig6){ref-type="fig"}). Next, egg counts were performed. Eggs deposited within the mesenteric system progress through the intestinal mucosa for excretion from the host, thereby propagating the parasite life cycle ([@bib47]). Therefore, it is possible to determine whether drug treatment impacted parasite egg laying by counting eggs in sections of the large and small intestines. Control mice contained large numbers of viable eggs in both the small and large intestine. However, treatment with either ergotamine or PZQ resulted in a considerable reduction (96.3 ± 1.2 and 99.9 ± 0.1%, respectively) in intestinal egg burden ([Figure 6C](#fig6){ref-type="fig"}). We also assessed whether serotonergic manipulation influenced egg laying in worms cultured ex vivo ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Egg laying was decreased following treatment with ergotamine (1 µM, 54.2 ± 12.6% reduction), serotonin (100 µM, 82.4 ± 2.2% reduction) or forskolin (100 µM, 61.6 ± 12.6% reduction) ([Figure 6---figure supplement 1B&C](#fig6s1){ref-type="fig"}). Eggs laid by ergotamine treated worms were often small and deformed, indicating abnormal development ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). We conclude ergotamine was highly effective at blocking parasite egg production and development.

Next, liver and spleen sizes were measured. A consequence of the enormous production of schistosome eggs is a host Th2 wave ([@bib26]) that drives granuloma formation and fibrosis in affected peritoneal organs ([@bib46]). Hepatosplenomegaly is a hallmark of chronic schistosomiasis and splenomegaly and liver fibrosis are observed in the murine model ([@bib21]). This is reflected by comparison of the weights of uninfected mouse spleens (0.12 ± 0.02 g) and the spleens of infected littermates (\~6 fold enlargement, weighing 0.76 ± 0.20 g at 49 days p.i), or increases in liver mass (\~2 fold enlargement from 2.0 ± 0.3 g in uninfected mice to 4.8 ± 0.8 g in infected mice, [Figure 6D](#fig6){ref-type="fig"}). PZQ treatment (one week, starting at 42 days p.i) did not prevent spleen and liver enlargement ([Figure 6D](#fig6){ref-type="fig"}). There was no difference in the weights of the liver and spleen between PZQ-treated and vehicle treated infected mice ([Figure 6E and F](#fig6){ref-type="fig"}). This is likely due to the fact that, while PZQ is highly effective at eliminating worms at six weeks infection and beyond ([@bib52]; [@bib31]), sexual maturation and egg laying commence as early as 5 weeks post infection ([@bib52]), meaning that eggs deposited prior to treatment initiation still evoke an immune response which PZQ exposure does not ameliorate. In contrast to PZQ, ergotamine exposure prevented hepatosplenomegaly. Ergotamine reduced the infection-promoted increase in spleen mass by 55.8 ± 14.0% and liver mass by 52.0 ± 14.2% relative to vehicle treated controls ([Figure 6E and F](#fig6){ref-type="fig"}). Similarly, liver sections from ergotamine-treated infections displayed decreased granuloma formation and fibrosis when investigated by various staining methods ([Figure 6G](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Movat\'s stain and Masson's trichrome showed decreased levels of collagen deposition surrounding granulomas ([Figure 6G,II--III](#fig6){ref-type="fig"}). Aldehyde fuchsin stain showed elastin surrounding the granulomas of DMSO and PZQ treated mice, while the livers of uninfected or ergotamine treated mice exhibited little staining ([Figure 6G,IV](#fig6){ref-type="fig"}). Oil red O staining revealed lipid stores present in the livers of uninfected mice that were absent in infected control livers. Treatment with ergotamine, but not PZQ, preserved regions of Oil red O positive staining - albeit at lower levels than healthy livers ([Figure 6G,V](#fig6){ref-type="fig"}). Pro-apoptotic cleaved caspase-3 was present in cells within granulomas of all three infected livers (DMSO control, ergotamine and PZQ treated -- [Figure 6G,VI](#fig6){ref-type="fig"}).

Finally, we tested whether ergotamine displayed efficacy as a treatment against immature infections, where PZQ is ineffective ([@bib52]). Both 5-HT and ergotamine stimulated movement of juvenile worms ex vivo ([Figure 6---figure supplement 3A and B](#fig6s3){ref-type="fig"}). In vivo, however, early dosing with ergotamine prior to egg laying (3--4 weeks post infection) did not resolve infections, mirroring the lack of effect of PZQ ([Figure 6---figure supplement 3C](#fig6s3){ref-type="fig"}).

In conclusion, these data show that ergotamine was highly effective at promoting survival in mice with mature infections ([Figure 6A](#fig6){ref-type="fig"}) through reductions in worm ([Figure 6B](#fig6){ref-type="fig"}) and egg number ([Figure 6C](#fig6){ref-type="fig"}). However - unlike PZQ - ergotamine was effective at attenuating hepatosplenomegaly associated with the chronic pathology of schistosomiasis.

Ergotamine impairs activation of hepatic stellate cells {#s2-6}
-------------------------------------------------------

How does ergotamine treatment protect against hepatosplenomegaly resulting from schistosome infection? Both ergotamine and PZQ clear parasites, but unlike ergotamine, PZQ-treated mice did not show a noticeable difference in liver and spleen size relative to control infections ([Figure 6](#fig6){ref-type="fig"}). As ergotamine is a human therapeutic with affinity for various host GPCRs ([@bib43]), in addition to high affinity for schistosome 5-HT receptors ([Figure 3D](#fig3){ref-type="fig"}), engagement of host signaling pathways likely underpins these protective effects.

To investigate mechanisms contributing to the differential in vivo effects of these drugs, we performed RNA-Seq analyses on the livers and spleens of schistosome-infected mice following drug treatment (PZQ, ergotamine) over a window 6 to 7 weeks post-infection ([Figure 7A](#fig7){ref-type="fig"}). Livers and spleens of infected mice showed widespread changes in gene expression relative to uninfected littermates; of the 24,421 transcripts with mapped sequencing reads, 9684 transcripts were differentially expressed in infected livers and 7325 transcripts were differentially expressed in infected spleens. It is well established that the host pathology of schistosomiasis infection is driven by an initial Th1 response to the worms themselves followed by a sustained Th2 response that drives egg-induced fibrosis (reviewed in \[[@bib46]; [@bib59]\]). Such a gene expression signature has been observed in numerous studies on livers or spleens of infected mice ([@bib53]; [@bib4]; [@bib25]; [@bib49]) and is borne out here through our data comparing infected and uninfected controls. Most components of Th1 and Th2 signaling pathways were significantly changed in both infected livers and spleens relative to uninfected littermates ([Figure 7B and C](#fig7){ref-type="fig"}).

![Effect of ergotamine on immune response and hepatic stellate cell activation.\
(**A**) Schematic of schistosome infection and drug treatment cohorts analyzed. Livers and spleens were harvested from infected mice treated with vehicle control, ergotamine (ERG 60 mg/kg, twice daily for 7 days) or praziquantel (PZQ 50 mg/kg, once daily for 5 days), as well as uninfected littermate controls. Five mice were used per cohort. (**B**) Volcano plots showing transcriptional changes of the liver and spleens from infected mice compared to uninfected littermates. Green shading highlights gene products involved in Th1/Th2 cell signaling. (**C**) Heat map of liver (**L**) and spleen (**S**) changes in Th1 and Th2 signaling pathways - color intensity corresponds to significance (FDR adjusted p-values). (**D--G**) Effects of anthelmintics on hepatic gene expression of schistosome infected mice. (**D**) Top left - differentially expressed transcripts comparing the livers of infected controls to uninfected littermates (grey), PZQ-treated animals (red) and ERG-treated animals (blue). Top right - expression of transcripts either up-regulated or down-regulated in infected livers relative to uninfected livers (z score ≥1 or ≤−1) in control and drug treated animals. Bottom, transcripts differentially expressed between PZQ-treated or ERG-treated and control infections represent pathways involved in liver function, drug metabolism and immune response. Ingenuity Pathway Analysis enrichment scores reflect -log~10~ p-value of PZQ and ERG datasets (p-value 0.05 = -log~10~ 1.3). (**E**) Filtering of transcripts changing with schistosomiasis infection that are affected by ERG but not PZQ, resulting in an enrichment for gene products involved in hepatic fibrosis/HSC activation. (**F**) Role of various gene products in HSC activation, and (**G**) read counts for these transcripts across uninfected (open box), infected (grey box) and ERG-treated (blue box) and PZQ-treated (red box) cohorts. Box plots represent 25--75 percentile, whiskers 5--95 percentile. Inset; bar = median, square = mean. Read count data for liver and spleen samples available in [Supplementary files 2](#supp2){ref-type="supplementary-material"} and [3](#supp3){ref-type="supplementary-material"}.](elife-35755-fig7){#fig7}

Drug treatment with either PZQ or ergotamine attenuated transcriptional changes associated with infection. The identity of transcripts changing with drug treatment (either with PZQ or with ergotamine treatment versus control infections) largely overlapped with those changing with infection (uninfected animals versus control infections) but as expected drug-treatment was associated with a decrease of transcripts up-regulated in control infections (relative to uninfected animals) or an increase of transcripts down-regulated in control infections (relative to uninfected animals, [Figure 7D](#fig7){ref-type="fig"}). Specifically, PZQ or ergotamine treatment decreased expression of pathways associated with host immune response to either parasites (acute phase response signaling, Th1 and Th2 pathway) or bacteria entering the circulation with the breakdown of the intestinal epithelium that occurs with heavy parasite egg production ultimately leading to host death (LPS/IL-1 mediated inhibition of RXR function \[[@bib22]; [@bib57]\]). Expression of pathways associated with drug metabolism (xenobiotic metabolism signaling) and liver function (hepatic cholestasis) increased with both treatments ([Figure 7D](#fig7){ref-type="fig"}). These observations that the PZQ and ergotamine cohorts shared similar transcriptional patterns relative to control infection is consistent with both treatments resolving infection and parasite egg production ([Figure 6B and C](#fig6){ref-type="fig"}).

Next, we sought to filter the transcriptomic dataset to identify transcriptional changes unique to ergotamine treatment ([Figure 7E](#fig7){ref-type="fig"}). This involved selecting transcripts that (i) displayed significant changes between uninfected and control infection cohorts, and (ii) were differentially expressed between control infection and ergotamine-treated cohorts, and (iii) showed little change between control infection and praziquantel treated cohorts ([Figure 7E](#fig7){ref-type="fig"}). Ingenuity pathway analysis using this triple-filtered criteria identified a cohort of transcripts uniquely associated with ergotamine, but not PZQ, treatment. These transcripts were tagged for involvement in hepatic fibrosis and hepatic stellate cell (HSC) activation (p-value 0.00015, Fisher\'s exact test). Ergotamine treatment down-regulated gene products associated with HSC activation to control infections, while PZQ treatment had little to no effect on the same suite of transcripts. HSCs represent a quiescent, non-proliferative cell population in normal liver but once activated during injury or disease, drive fibrotic responses by transforming into proliferative, contractile myofibroblasts that deposit extracellular matrix components ([@bib54]). Differentially expressed transcripts in ergotamine-treated samples ([Supplementary file 4](#supp4){ref-type="supplementary-material"}) included known markers of HSC activation responsible for extracellular matrix production (*COL1A1, COL1A2, COL3A1*), transcripts associated with HSC contraction (*CACNA1E, CACNA1H*), migration (*IGFBP3, RANTES*), survival (*IGFBP5, GAS6*) and transdifferentiation into myofibroblasts (*MMP13, GLI1, PAK1*) ([Figure 7F and G](#fig7){ref-type="fig"}). Ligands that control HSC activation and survival were also differentially expressed (*PDGFB, IL13RA2, BMP4, IL-4, SAA*).

Therefore, ergotamine and PZQ were both effective at promoting survival ([Figure 6A](#fig6){ref-type="fig"}) through reductions in worm ([Figure 6B](#fig6){ref-type="fig"}) and egg number ([Figure 6C](#fig6){ref-type="fig"}), as well as reversing many transcriptional signatures that drive host pathological outcomes in response to parasite infection ([Figure 7D](#fig7){ref-type="fig"}). However, unlike PZQ, ergotamine was also effective at attenuating the hepatosplenomegaly associated with the chronic pathology of schistosomiasis ([Figure 6D--G](#fig6){ref-type="fig"}), due to decreased activation of profibrotic HSCs ([Figure 7E--G](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

Given the importance of serotonergic signaling in parasite physiology, the possibility of serotonergic drugs providing effective antiparasitic agents has long been recognized ([@bib38]). With a defined molecular target (a prevalent schistosome 5-HTR cloned from each of the main species that cause schistosomiasis) and an optimized functional profiling assay for this GPCR ([Figure 1](#fig1){ref-type="fig"}), we have now been able to investigate this possibility. Here, we screened thousands of compounds in vitro ([Figure 2](#fig2){ref-type="fig"}) and interpolated structure-activity studies on promising chemical series ([Figure 3](#fig3){ref-type="fig"}). These cell-based assays yielded candidates for ex vivo screening against adult parasites ([Figure 4](#fig4){ref-type="fig"}), and thereby prioritization of the most active compounds for in vivo testing in a mouse model of schistosomiasis ([Figure 5](#fig5){ref-type="fig"}). This pipeline identified unique properties of ergotamine, an ergot alkaloid first isolated 100 years ago ([@bib29]) and FDA-approved medication for migraine, for treating schistosomiasis. Ergotamine increased survival in a murine model of schistosomiasis through reductions in parasite burden and resultant egg load, but most intriguingly resolved inflammatory damage caused by schistosome eggs laid in host tissues, an effect not observed with PZQ under the same conditions ([Figure 6](#fig6){ref-type="fig"}). These effects likely result from the broad polypharmacology of ergotamine that coalesces a fortuitous combination of effects at both host and parasite GPCRs.

Action on parasite {#s3-1}
------------------

Ergotamine is a potent Sm.5HTR~L~ agonist ([Figure 3](#fig3){ref-type="fig"}). Sm.5HTR~L~ and homologs of this receptor in other flatworms, regulate movement ([@bib45]; [@bib8]). Sm.5HTR~L~ is downregulated upon pairing of adult *S. mansoni* females and males, implicating an additional role in sexual maturation ([@bib37]). As a G~s~ coupled receptor, the role of 5-HT acting through cAMP to regulate flatworm metabolism is also relevant ([@bib39]). These broad physiological roles - motor function, female egg production, metabolism -- underscore consideration of Sm.5HTR~L~ as an attractive antischistosomal target. Screening hits ([Figure 2](#fig2){ref-type="fig"}), and subsequent structure-activity studies ([Figure 3](#fig3){ref-type="fig"}) confirmed the ergoline core as a customizable scaffold for ligand optimization at Sm.5HTR~L~. These analyses provided a toolbox of compounds with varied potencies and efficacies against Sm.5HTR~L~in vitro and Sm.5HTR~L~ agonists and antagonists stimulated and inhibited adult worm motility ex vivo as predicted ([Figure 4](#fig4){ref-type="fig"}). However in vivo, only agonists of Sm.5HTR~L~ signaling caused a hepatic shift of worms and mitigated worm burden, Sm.5HTR~L~ blockers were ineffective ([Figure 5](#fig5){ref-type="fig"}). This observation was surprising given the presumed beneficial effect of causing potent (BOL-148) or long-lasting (bromocriptine) worm paralysis ([@bib10], [@bib17]), but nevertheless informative for future phenotypic screens to prioritize 'hyperactive' over 'hypoactive' serotoninergic hits. From these analyses, ergotamine emerged as a potent full agonist ([Figure 3D](#fig3){ref-type="fig"}) that stimulated movement ex vivo ([Figure 4C](#fig4){ref-type="fig"}) and reduced worm and disease burden in vivo ([Figure 6](#fig6){ref-type="fig"}).

Action on host {#s3-2}
--------------

While ergotamine stimulates schistosome movement through 5.HTRs, the drug also acts on host GPCR targets. Ergotamine is known to display a broad polypharmacology, interacting with numerous bioaminergic GPCRs ([@bib43]). These interactions likely engage physiological responses that mitigate the damage caused by egg laying and possibly contribute to worm elimination. Acutely, ergotamine acts as a vasoconstrictor, including within the mesenteric vasculature where the adult worms reside ([@bib42]). Disruption of the parasite environment consequent to ergotamine-evoked mechanical changes and alterations of blood flow within the hepatic portal system could drive parasites from the mesenteries to the liver for elimination. This action would mirror recent data demonstrating R-PZQ, which also causes a hepatic shift, acts a human 5-HT~2B~ receptor partial agonist that contracts host mesenteric vessels ([@bib9]). Chronically, drug treatment with either PZQ or ergotamine improved various aspects of liver function (hepatic cholestasis, retinol metabolism, bile acid synthesis, [Figure 7D](#fig7){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}) relative to untreated infections. Beneficial changes highlighted by RNA-Seq also encompassed protection against intestinal damage ([@bib6]). Various pathways involved in response to bacterial infection were down regulated with PZQ and ergotamine treatment relative to control infections ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). This is likely because mice experience a relative infection burden orders of magnitude higher than typical for humans ([@bib12]) resulting in compromised intestinal integrity and release of microbiota into the circulation as mature parasites commence egg production. These effects likely contribute to the observed lethality post-infection and are shown to be mitigated by both drug treatments in the RNA-Seq analysis.

However, ergotamine additionally provided protection against the spleen and liver enlargement that persisted in PZQ-treated mice ([Figure 6D and E](#fig6){ref-type="fig"}), suggesting a further action of ergotamine on the host immune response. Analysis of RNA-Seq datasets identified transcriptional changes unique to ergotamine and not PZQ treatment, most notably a decrease in gene products involved in hepatic fibrosis ([Figure 7E--G](#fig7){ref-type="fig"}). Hepatic stellate cells (HSCs) are key drivers of fibrosis during liver disease. Upon their transformation into myofibroblasts, HSCs initiate active production of extracellular matrix components (collagen, elastin -- [Figure 6G,II-IV](#fig6){ref-type="fig"}) and decrease lipid storage ([Figure 6G,V](#fig6){ref-type="fig"}, \[[@bib54]\]). HSCs are known to express a portfolio of GPCRs that regulate activation and transformation ([@bib54]). These include several serotonergic GPCRs (5HT~1B~, 5HT~1F~, 5HT~2A~, 5HT~2B~, 5HT~7~, \[[@bib51]\]). It is tantalizing that the known polypharmacological signature of ergotamine ([@bib43]) closely matches the serotoninergic GPCR expression profile in HSCs ([@bib51]). This may imply a cell-autonomous action of ergotamine on HSCs, although further insight would be needed to distinguish this possibility from non cell-autonomous mechanisms given that serotonin impacts immune responses and liver regeneration in a multiplicity of ways ([@bib28]; [@bib36]; [@bib18]). For example, ergotamine could impair HSCs indirectly by inhibiting macrophage polarization ([@bib15]) or immune mediators such as TNF-α and ICAM-1 (54). ICAM-1 is found at elevated levels within egg-evoked granulomas ([@bib50]) and TNF-α drives the host immune response to schistosome eggs ([@bib1]; [@bib35]). Prior studies on schistosome infection of immune compromised mice have shown that T-cell deprived mice exhibit hepatic microvesicular steatosis, since granulomas also have a beneficial function of facilitating excretion of eggs from the mesenteries and sequestering toxic egg products (reviewed in \[[@bib27]; [@bib16]\]). Ergotamine treatment impaired the granulomatous response to eggs ([Figure 6G](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), but increased microvascular damage was not observed ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). Additional experiments will be needed to investigate stellate cell responsiveness and whether ergotamine is effective against other parasitic diseases currently treated with PZQ.

While the polypharmacology of ergotamine evidences the principle of combining host and parasite responses for therapeutic effect, it is not itself a likely candidate for repurposing. Repeated dosing of ergotamine as an antimigraine therapy is associated with known side effects: it is contraindicated in pregnancy and poorly suited for the large pediatric population susceptible to schistosomiasis. For future studies, analogs with improved pharmacokinetic profile and bioavailability will need to be evaluated for clinical potential as safe and effective agents. Indeed, for treatment of parasitic infections, a single bolus dose may provide more flexibility and avoid cumulative side effects associated with repeated dosing. Our limited structural-activity studies to date (e.g. [Figure 3](#fig3){ref-type="fig"}) on schistosome GPCRs do suggest modifications of the core ergot alkaloid scaffold can generate analogs with a range of potencies and efficacy.

In conclusion, ergotamine is fortuitously suited to engage pathways in both host and parasite that are simultaneously deleterious to the blood fluke but beneficial to the infected host in terms of worm clearance and mitigation of damage caused by eggs. Rather than prioritizing 'selective' antiparasitic therapies with no host effects, these data demonstrate merit in evaluating agents with broader polypharmacology across parasite and host as a route to novel discovering effective treatments for parasitic disease.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation               Source or reference   Identifiers               Additional information
  or resource                                                                                            
  ---------------------------- ------------------------- --------------------- ------------------------- ---------------------------------
  Cell line                    HEK293 cells              Company               ATCC; CRL-1573            

  Biological sample\           *Schistosoma*\            Stock Center          BEI: NR-34792             Biodefense and Emerging\
  (*Schistosoma mansoni*)      *mansoni*                                                                 Infections Research Resources\
                                                                                                         Repository (BEI Resources)

  Biological sample\           *Schistosoma*\            Stock Center          BEI: NR-45100;\           Biodefense and Emerging\
  (*Schistosoma japonicum*)    *japonicum*                                     BEI:NR-45101              Infections Research Resources\
                                                                                                         Repository (BEI Resources)

  Biological sample\           *Schistosoma*\            Stock Center          BEI: NR-45102;\           Biodefense and Emerging\
  (*Schistosoma hematobium*)   *hematobium*                                    BEI:NR-45103              Infections Research Resources\
                                                                                                         Repository (BEI Resources)

  Recombinant DNA\             Sm.5HTRL                  Data repository       GenBank accession\        
  reagent                                                                      KX150867                  

  Recombinant DNA\             Sj.5HTR                   Data repository       GenBank accession\        
  reagent                                                                      number MG813904           

  Recombinant DNA\             Sh.5HTR                   Data repository       GenBank accession\        
  reagent                                                                      number MG813903           

  Commercial assay\            GloSensor 22F cAMP\       Company               Promega; E2301            
  or kit                       sensor                                                                    

  Commercial assay\            D-luciferin sodium salt   Company               Gold Biotechnology;\      
  or kit                                                                       LUCK-100                  

  Commercial assay\            Cleaved caspase −3        Company               Biocare; CP-229C          
  or kit                                                                                                 

  Chemical compound,\          NCI Natural Products\     Other                                           National Institutes of Health,\
  drug                         Set IV                                                                    NCI Development Therapeutics\
                                                                                                         Program (DTP)

  Chemical compound,\          Natural Product Library   Company               TimTec: NPL-800           
  drug                                                                                                   

  Chemical compound,\          Natural Derivatives\      Company               TimTec: NDL-3000          
  drug                         Library                                                                   

  Chemical compound,\          LSD                       Other                 NIDA; 7315--006           National Institute on Drug\
  drug                                                                                                   Abuse (NIDA)

  Chemical compound,\          BOL-148                   Other                 NIDA; 7315--010           National Institute on Drug\
  drug                                                                                                   Abuse (NIDA)

  Chemical compound,\          PZQ - praziquantel        Company               Sigma Aldrich:\           
  drug                                                                         P4668-1G                  

  Chemical compound,\          ergotamine                Company               Sigma Aldrich:\           
  drug                                                                         1241506--150 MG           

  Chemical compound,\          dihydroergotamine         Company               Sigma Aldrich:\           
  drug                                                                         D1952000                  

  Chemical compound,\          bromocriptine             Company               Sigma Aldrich:\           
  drug                                                                         B2134-100MG               

  Chemical compound,\          IBMX                      Company               Sigma Aldrich:\           
  drug                                                                         I5879-100MG               

  Chemical compound,\          LAMPA                     Company               Cerilliant: L-004--1 ML   
  drug                                                                                                   

  Chemical compound,\          Lisuride                  Company               Tocris: 4052              
  drug                                                                                                   

  Chemical compound,\          dihydroergotoxine         Company               Tocris: 0474              
  drug                                                                                                   

  Chemical compound,\          methylergometrine         Company               Tocris: 0549              
  drug                                                                                                   

  Chemical compound,\          forskolin                 Company               Cell Signaling\           
  drug                                                                         Technology: 3828          

  Software, algorithm          HISAT2                    PMID: 25751142                                  

  Software, algorithm          edgeR                     PMID: 19910308                                  

  Software, algorithm          Ingenuity Pathway\        Company               QIAGEN Bioinformatics:\   
                               Analysis                                        IPA                       

  Software, algorithm          DAVID Bioinformatics\     Other                                           Laboratory of Human\
                               Resources 6.8                                                             Retrovirology and\
                                                                                                         Immunoinformatics (LHRI)
  ----------------------------------------------------------------------------------------------------------------------------------------

Molecular cloning {#s4-1}
-----------------

The sequence for Sm.5HTR~L~ (GenBank accession KX150867 \[[@bib10]\]) was used to BLAST the *S. haematobium* and *S. japonicum* genomes for putative homologs. The resulting *S. haematobium* (NCBI Reference Sequence XM_012944163 and XM_012944164) and *S. japonicum* (GenBank FN332592.1) hits were used as templates to clone out full-length mRNA sequences by 5' and 3' RACE (Marathon cDNA Amplification Kit, Clontech) using *S. haematobium* and *S. japonicum* total RNA provided by the Schistosomiasis Resource Center. Finalized sequences have been deposited with NCBI (Sh.5HTR = GenBank accession number MG813903, Sj.5HTR = GenBank accession number MG813904). Plasmids for heterologous expression were generated by codon optimization of the coding sequence for mammalian expression and subcloning into either pcDNA3.1(-) (between *Not*I and *Eco*RI) or pEGFP-N3 (*Eco*RI).

Cell lines and culture {#s4-2}
----------------------

HEK293 cells (ATCC CRL-1573, an authenticated cell line validated by STR profiling) were cultured in growth media consisting of DMEM supplemented with GlutaMAX (Gibco cat \# 10566016) + 10% heat inactivated fetal bovine serum and penicillin-streptomycin (100 units/mL, ThermoFisher). Stable cell lines for the pGloSensor-22F cAMP Plasmid (Promega) and schistosome 5HTRs in pcDNA3.1(-) were selected with hygromycin (200 µg/mL) and G418 (400 µg/mL). The correct identity of each stably expressed sequence was verified by isolating total RNA from each stable line (TRIzol Reagent, Ambion) and amplifying the sequence of interest with gene specific primers flanking the 5' and 3' regions of the coding sequence (SuperScript III One-Step RT-PCR System, Invitrogen). PCR products were ligated into a TA cloning vector (pGEM-T Easy, Promega) and verified by Sanger sequencing.

cAMP luminescence assays {#s4-3}
------------------------

HEK293 lines stably expressing both the GloSensor 22F cAMP sensor and Sm.5HTR~L~ were cultured in growth media supplemented with 10% dialyzed FBS. For cAMP assays in 96 well format, cells cultured in T-75 flasks were trypsinized (TrypLE Express, Gibco) and plated in solid white 96 well plates (Costar cat \# 3917) the day prior to assay at a density of 2.5 × 10^4^ cells/well. The following day media was removed and replaced with assay buffer consisting of HBSS buffered with HEPES (20 mM, pH 7.4) + BSA (0.1% w/v) and D-luciferin sodium salt (1 mg/mL, Gold Biotechnology). Plates were equilibrated at room temperature for 1 hr, at which point 3-Isobutyl-1-methylxanthine (IBMX 200 µM, Sigma Aldrich) was added. Plates were equilibrated a further 30 min prior to test compound addition. Test compounds were added and luminescence was read for 45 min on a GloMax-Multi Detection System plate reader (Promega) to screen for agonists, after which plates were removed, 5-HT was added to each well at a concentration determined to achieve a maximal response for each stable cell line (Sm.5HTR~L~ = 500 nM, Sj.5HTR = 500 nM, Sh.5HTR = 60 nM), and plates were read a second time to screen for antagonist activity. Readings performed in 384 well format were modified so that cells were assayed in suspension. Cells were grown to 70% confluence in T-75 flasks, trypsinized and pelleted (300 RCF x 5 min). Media was removed and cells were resuspended in 25 mL assay buffer supplemented with IBMX (200 µM). A 96 channel semi-automated pipet (Eppendorf epMotion 96) delivered 55 µL of cell suspension per well (5000 cells/well) into solid white 384 plates (Corning 3574). After one hour of equilibration, test compounds were screened at a fixed concentration of 10 µM, and control wells (64 wells per plate) were treated with vehicle alone (1% DMSO in HBSS), providing an internal negative control reference. Following 60 min incubation at ambient temperature, plates were read for agonist activity, defined as a \>10 fold increase in luminescence relative to control, DMSO treated wells on the same plate. Serotonin (1 µM) was then added to each well, and after 60 min the plate was read again to identify compounds with antagonist activity, defined as compounds that inhibiting 5-HT evoked signal by \>90% relative to control wells. The initial high-throughput screen in 384 well format was performed as a single replicate, with all 'hits' meeting agonist or antagonist thresholds re-screened in 96 well format (technical quadruplicates performed for three biological replicates). Counter screening of primary hits against the parental HEK293 cell line expressing the GloSensor 22F cAMP sensor and lacking Sm.5HTR~L~ was performed to eliminate compounds stimulating cAMP (\>3 fold change in basal luminescence) or inhibiting forskolin evoked cAMP production (\>25% inhibition relative to DMSO controls).

Reagents and chemicals {#s4-4}
----------------------

A complete list of chemical vendors, catalog numbers and SMILES is contained in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Natural product libraries were sourced from the National Institutes of Health (NCI Natural Products Set IV) and TimTec (Natural Product Library \[NPL-800\] and Natural Derivatives Library \[NDL-3000\]). LSD and BOL-148 were sourced from the National Institute on Drug Abuse (NIDA). The following compounds were sourced from Sigma Aldrich: praziquantel (PZQ, P4668-1G), ergotamine tartrate (1241506--150 MG), dihydroergotamine tartrate (D1952000), bromocriptine (B2134-100MG). LAMPA was sourced from Cerilliant (L-004--1 ML). Lisuride maleate (4052), dihydroergotoxine mesylate (0474) and methylergometrine maleate (0549) were sourced from Tocris.

Ethics statement {#s4-5}
----------------

All animal experiments followed ethical regulations approved by the Medical College of Wisconsin and Iowa State IACUC committees and additionally reviewed in the context of funding by the National Institutes of Health (NIAID).

Ex vivo schistosome assays {#s4-6}
--------------------------

Female Swiss Webster mice infected with *S. mansoni* cercariae (NMRI strain) were sacrificed 49 days post infection by CO~2~ euthanasia. Adult schistosomes were recovered by dissection of the mesenteric vasculature. Harvested schistosomes were washed in RPMI 1640 Medium with GlutaMAX + 5% heat inactivated FBS (Gibco) and Penicillin-Streptomycin (100 units/mL).

For movement assays, worms were cultured 37°C and 5% CO~2~ in vented 100 × 25 mm petri dishes (ThermoFisher cat \# 4031) containing 50 mL of media and used 1--3 days after harvesting. Prior to assessing worm movement, male worms were transferred to a six well dish (4--5 individual worms per well) containing 3 mL drug solution in RPMI 1640 supplemented with HEPES (25 mM) and FBS (5%). Videos were recorded using a Zeiss Discovery v20 stereomicroscope and a QiCAM 12-bit cooled color CCD camera controlled by Metamorph imaging software (version 7.8.1.0). 1 min recordings were acquired at 4 frames per second, saved as a. TIFF stack, and movement was analyzed using ImageJ software as described in ([@bib10], [@bib7]). Data represents mean ± standard error for ≥3 independent experiments. EC~50~ and IC~50~ values are reported ± 95% confidence interval of fitted curves.

For egg laying assays, adult schistosomes were transferred to 24 well plates the day after harvesting from mice (5 pairs of male and female worms in 2 mL media/well). Eggs were counted daily using a stereomicroscope, after which worms were transferred to a new well with fresh drug-containing media. Egg counts were recorded for 5 days, and data processed as the mean number of eggs laid per worm pair per day. Measurements of egg dimensions were quantified using the 'analyze\>measure' function in ImageJ to record the length and width of individual eggs.

In vivo schistosome drug screening {#s4-7}
----------------------------------

Female Swiss Webster mice were exposed to 200 *s. mansoni* cercariae (NMRI strain) at between 4--6 weeks old. For hepatic shift assays, infections matured to 7 weeks, at which point mice were given test compounds by intraperitoneal injection and euthanized 3 hr later. Compounds were solubilized in 50 µL DMSO, and diluted in 200 µL 5% w/v Trappsol (Cyclodextrin Technologies Development, THPB-p-31g) in saline (NaCl 0.9%) solution. Immediately after being euthanized, mice were dissected to separate the liver from the portal vein, so that the number of worms recovered from the portal vein, mesenteric vasculature and liver could be recorded for each mouse. Hepatic shift assays were performed on at least 3 mice per drug treatment. Assays testing the curative efficacy of compounds against schistosome infections were performed on mice at 3 weeks post infection (immature parasites) and 6 weeks post infection (mature parasites). Drugs were dosed as follows. Ergotamine (60 mg/kg) was solubilized in 50 µL DMSO and diluted in 200 µL Trappsol-saline and delivered by intraperitoneal injection twice a day for one week. Praziquantel (50 mg/kg) was similarly solubilized and injected intraperitoneally once a day for one week. The negative control cohort was given twice daily injections of DMSO (50 µL) added to 200 µL Trappsol-saline solution. Mice were weighed and euthanized at 49 days post infection. Worms were harvested and counted as described for the hepatic shift assay. Spleen and livers were weighed, and a segment of intestine was excised from the most distal region of the rectum to 10 cm above the cecum. The small and large intestines were separated by cutting immediately above and below the cecum. Each was cut lengthwise to expose the lumen and thoroughly washed in NaCl (1.2%) to remove excrement. Intestines were laid flat with the intestinal mucosa facing upwards and clamped between two glass plates to allow visual inspection of egg morphology and number using a stereo microscope. Scored egg counts reflect 'viable' eggs containing a developing embryo or a mature miracidium, while empty egg shells and granulomas were not included ([@bib47]; [@bib40]).

Liver histology and immunohistochemistry {#s4-8}
----------------------------------------

Mouse livers were removed immediately after animals were euthanized, rinsed in ice cold PBS, and fixed in 10% neutral buffered formalin. For H and E stain, Movat's stain, Masson's trichrome, and aldehyde fuchsin staining, samples were embedded in paraffin and sectioned at 4 microns (Microm HM355S). For Oil red staining, livers were equilibrated in freezing medium (10% w/v and then 30% w/v sucrose solution in PBS) prior to cryosectioning (Leica CM1850 UV Cryostat). If paraffin embedded, slides were deparaffinized, hydrated, and the following staining procedures were then performed: *H and E stain,* slides were stained with Harris hematoxylin and eosin working solution (Poly Scientific). *Movat's stain,* Alcian blue (1% w/v), hematoxylin (10%), crocein scarlet --acid fuchsin solution, and alcoholic saffron (6.5% w/v). *Masson's trichrome,* slides were pre-treated with Bouin's solution and successively stained with hematoxylin, Biebrich-Scarlet-Acid Fuchsin and Aniline Blue solution. *Aldehyde Fuchsin.* slides were stained with aldehyde fuchsin and counterstained with fast green. *Oil red O staining,* after cryosectioning onto Superfrost slides (Fisherbrand), samples were stained with Oil Red (0.3% w/v in 60% isopropanol) followed by hematoxylin counterstain. *Cleaved Caspase-3 staining,* slides were treated with Leica BOND Epitope Retrieval Solution 2 (20 min), peroxidase-blocking solution (Dako), avidin/biotin blocking kit (Vecgtor) and background sniper blocking reagent (Biocare) per manufacturer's instructions. This was followed by Cleaved Caspase-3 primary antibody incubation (Biocare, CP-229C) at 1:100 dilution for 90 min at room temperature, 3 × 1 min washes (Lieca BondTM Wash Solution), and incubation in biotinylated secondary antibody (Jackson Immuno, 771-066-152) at 1:500 dilution for 30 min, 3 × 1 min washes, and finally incubation in Streptavidin HRP (Dako, P0397) at 1:300 dilution. After washing (3 × 1 min), staining was visualized using DAB + Substrate Chromogen System (Dako, K3468). As a negative control, samples were treated as stated above but without primary antibody.

Transcriptome sequencing {#s4-9}
------------------------

Mice were infected and treated with drugs as described above. After drug treatment from weeks 6--7 post infection, mice were euthanized and livers and spleens were immediately removed and placed on ice. For liver samples, a section of the larger, right lobe was excised and homogenized in TRIzol Reagent (Invitrogen). For spleen samples, the entire organ was homogenized in TRIzol. Samples were stored in −80°C until processed. Total RNA was extracted from TRIzol according to manufacturer's protocols and quantified with RiboGreen RNA Assay Kit. Libraries were generated using the Clontech StrandedRNA Pico Mammalian kit and sequenced using the Illumina HiSeq 2500 system (high-output mode, 50 bp paired-end reads) at a depth of approximately 20 million reads/sample. Trimmed reads were mapped to the mouse genome (mm10/GRCm38) using HISAT2. Expression was quantified using featureCounts (read counts) and cuffquant (FPKM). EdgeR was used to identify differentially expressed genes (tagwise dispersion model, adjusted p-value\<0.05) which were processed using Ingenuity Pathway Analysis (Qiagen) and DAVID functional annotation tool (version 6.8). RNA-Seq data has been deposited in the NCBI SRA database under accession number SRP131511.

Statistics {#s4-10}
----------

Metrics for evaluating cell based screening assays include coefficient of variation (CV%), signal window (SW), Z factor and Z' factor. Equations for each metric are included in the legend of [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}. Sample sizes for in vivo mouse experiments measuring worm burden were chosen to exceed minimum sample sizes determined by power calculations assuming a difference in means of 60%, standard deviation of 20%, power of 0.9 (β = 0.1) and significance criterion (α) of 0.05. Sample size for in vivo mouse survival analysis experiments also assumed a significance criterion (α) of 0.05 and power of 0.9 (β = 0.1), with half of the mice being treated with experimental drug and half with vehicle control and a hazard ratio of 5. RNA-Seq data was analyzed for differential expression in EdgeR which generated FDR adjusted p-values using the Benjamini-Hochberg method - transcripts with p-values under 0.05 were considered differentially expressed.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R21AI25821 to Jonathan S Marchant.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R21AI130642 to Jonathan S Marchant.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R01GM088790 to Jonathan S Marchant.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health F32AI124598 to John D Chan.

We thank the NIDA Drug Supply Program for providing reagents (LSD, 2-Bromo-LSD). Schistosome-infected mice were provided by the NIAID Schistosomiasis Resource Center at the Biomedical Research Institute (Rockville, MD) through NIH-NIAID Contract HHSN272201000005I for distribution via BEI Resources.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Formal analysis, Funding acquisition, Investigation, Visualization, Writing---original draft, Writing---review and editing.

Project administration, Writing---review and editing.

Conceptualization, Supervision, Funding acquisition, Visualization, Writing---original draft, Project administration, Writing---review and editing.

Animal experimentation: All animal experiments followed ethical regulations approved by the Medical College of Wisconsin IACUC committee (AUA00006079) and additionally reviewed in the context of extramural funding by the National Institutes of Health (NIAID).

Additional files {#s6}
================

10.7554/eLife.35755.017

###### Natural product library screening data.

(Sheet 1) Vendor, chemical identification (SMILES) and primary screening data for all natural product compounds screened against Sm.5HTR~L~. (Sheet 2) Counter screening data for agonist primary hits in cells expressing the 22F cAMP GloSensor and lacking Sm.5HTR~L~. (Sheet 3) Counter screening data for antagonist primary hits in cells expressing the 22F cAMP GloSensor and lacking Sm.5HTR~L~. NPS = NCI Natural Products Set IV, NPL = TimTec Natural Product Library, NDL = TimTec Natural Derivatives Library.

10.7554/eLife.35755.018

###### RNA-Seq data of drug treated and control infected mouse livers.

Read counts for uninfected control, infected control, infected ergotamine-treated and infected praziquantel treated liver samples.

10.7554/eLife.35755.019

###### RNA-Seq data of drug treated and control infected mouse spleens.

Read counts for uninfected control, infected control, infected ergotamine-treated and infected praziquantel treated spleen samples.

10.7554/eLife.35755.020

###### Signaling pathways enriched in drug treated livers relative to control infections.

Ingenuity Pathway Analysis (IPA) of transcripts differentially expressed in livers of PZQ (Sheet 1) and ergotamine (Sheet 2) treated mice relative to control infections. IPA generated activation Z-scores are shown if magnitude ≥2. KEGG pathway analysis of transcripts differentially expressed in livers of PZQ (Sheet 3) and ergotamine (Sheet 4) treated mice relative to control infections.

10.7554/eLife.35755.021

Data availability {#s7}
-----------------

RNA-Seq data has been deposited in the NCBI SRA database under accession number SRP131511.

The following dataset was generated:

Chan JDDay TAMarchant JS2018RNA-Seq of schistosome infected mus musculus: adult female liver<https://www.ncbi.nlm.nih.gov/sra?term=SRP131511>Publicly available at the NCBI Sequence Read Archive (accession no: SRP131511)
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Decision letter

Soldati-Favre

Dominique

Reviewing Editor

University of Geneva

Switzerland

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Coalescing beneficial host and deleterious antiparasitic actions as an antischistosomal strategy\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wenhui Li as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ray Pierce (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In the absence of vaccines and in light of the very limited repertoire of available treatments, the search for new drugs against schistosomiasis is a priority. Chan et al. report here an elegant and creative approach that led to an interesting set of findings on a target-based screen of a *Schistosoma* serotoninergic GPCR receptor. Ergotamine is identified as an agonist hit that negatively influences worm movement. In a mouse model ergotamine decreases mortality of schistosome-infected mice, parasite number, and egg load. At the same time ergotamine treatment also reduces organ pathology in the mouse liver through the engagement of host GPCRs, which suppress the activation of hepatic stellate cells as well as inflammatory damage and fibrosis. Based on high quality data, the authors conclude that ergotamine exerts dual affects by targeting host and parasite GPCRs with a deleterious outcome for the parasite and a beneficial effect for the host.

Essential revisions:

1\) Ergotamine is an alkaloid that shares structural similarity with neurotransmitters like dopamine. Acting as an agonist, this drug leads to vasoconstriction and is mainly prescribed for patients suffering from migraines. However, contraindications comprise among others hepatic disease, pregnancy, and the age of patients -- such as preschoolers. Since schistosomiasis mainly affects children, including preschoolers, and since it is also a hepatic disease, how safe or how problematic could this drug be for a patient?

According to the Mayo Clinic recommendations (last update: March 01, 2017), 1 -- 2 mg are recommended for adults. In case no side effects occur, a second and even a third dose can be taken; however, the doses should be taken at least 30 minutes apart, and should not exceed 3 mg per day. Ergotamine should not be taken by very young children (\< 6 years). And from 6 years on, or older, 1 mg is recommended with a maximum of 3 mg a day along with the restriction that this drug should not be taken by children more often than 2 times a week, at least five days apart. Against the background of these facts and the animal data from this study (60 mg/kg twice daily for one week in the mouse model), the low bioavailability in human (2%, when given as tablet; PMCID: PMC1428366), and the short half time of 2 -- 3 hours (https://druginfo.nlm.nih.gov/drugportal/rn/113-15-5), how realistic are the chances for ergotamine to become a drug repurposed for schistosomiasis?

The potential problems that may arise with the repurposing of this drug and the extensive clinical testing in the context of treatment for schistosomiasis should be addressed in the Discussion.

2\) The antiparasitic effect of ergotamine was accompanied by a marked apparent improvement in the pathological effects of infection on the host. The observed reduction in liver and spleen size and the improvement in liver morphology was found to correlate with an ergotamine-specific effect on hepatic stellate cells, and hence on liver fibrosis. A marked reduction in granuloma size and liver fibrosis is seen in congenitally athymic mice. However, in the case of *S. mansoni* infection, this leads to increased mortality and fewer eggs passed into the feces (Cheever et al., Am J Trop Med Hyg, 1993, 48:496-503). Byram and von Lichtenberg (Am J Trop Med Hyg, 1977, 26:944-56) suggested that the deficient granuloma formation led to failure to sequester toxic egg products, resulting in hepatocellular damage. Although smaller, the livers of ergotamine-treated, infected mice do not seem normal (Figure 5D) and have a darker color, even than control infected or PZQ-treated mice. Further, the picrosirius red-stained histological sections (Figure 5G) could be complemented with other staining methods to determine whether any hepatocyte necrosis is visible. It is important to show that the ergotamine effect on the host response is really beneficial.

3\) Do these compounds (e.g., ergotamine) have activity against other schistosome stages (schistosomules, juveniles). Those experiments could be done ex vivo for a start, and subsequently in vivo. This issue is an important one, as juvenile worms (2-4 weeks p.i.) are refractory to PZQ. The issue should at least be discussed. Also do these compounds have activity in motility assays (or, even better, in vivo) against other species of schistosomes? Based on the data in Figure 3, one would expect they would, but it would be nice to know.

4\) Why is mouse survival lower in ergotamine-treated than in PZQ-treated infected mice despite the ameliorating effects of ergotamine on pathology.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Coalescing beneficial host and deleterious antiparasitic actions as an antischistosomal strategy\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Wenhui Li (Senior Editor), a Reviewing Editor, and three reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed by editing the text before acceptance, as outlined below:

In their revised version, Chan et al. addressed a number of points raised by the reviewers.

With respect to my former comment that: \"contraindications comprise among others hepatic disease, pregnancy, and the age of patients -- such as preschoolers. Since schistosomiasis mainly affects children, including preschoolers, and since it is also a hepatic disease, how safe or how problematic could this drug be for a patient?\" the authors responded that they \"acknowledge the side effect profile of ergotamine and agree in the absence of preclinical data that speculation upon the human repurposing potential of ergotamine as a treatment is premature. \[...\] We have therefore removed previous text speculating on the repurposing potential of ergotamine throughout the manuscript text. Additionally, we note: (i) our SAR studies (Figure 3) underscore the potential for manipulation of the core ergot alkaloid pharmacophore to develop analogs with varied efficacy, and potentially improved PK/PD, (ii) treatment of parasitic diseases with a single bolus dose of drug may provide more flexibility than dosing parameters established on the basis of cumulative side effects from repeated drug dosing.\"

In their marked version, however, it is not possible to follow these deletions since appropriate positions have not been marked as deleted within the text. Please indicate the \"removed previous text speculating\" clearly. Furthermore, I miss comments within the manuscript with respect to \"the potential for manipulation of the core ergot alkaloid pharmacophore to develop analogs with varied efficacy, and potentially improved PK/PD\". The chapter \"Structural determinates of activity at schistosome 5-HTRs\" ends with \" ergotamine (compound \'1) as the most potent, full agonist and 2-Bromo-LSD (compound \'20\') as the most potent antagonist for further evaluation.\" Unfortunately, also the Discussion fails to discuss this point critically. Instead, the Discussion ends with the conclusion that \"\[...\] ergotamine is fortuitously suited to engage pathways in both host and parasite that are simultaneously deleterious to the blood fluke but beneficial to the infected host in terms of worm clearance and mitigation of damage caused by eggs\". This is suggestive for its repurposing potential, even without mentioning this word.

In the Abstract the authors mention that \"Conventional approaches for antiparasitic drug discovery center upon discovering selective agents that adversely impact parasites with minimal host side effects\". Especially the latter seems not applicable against the background of all known contradictions of ergotamine, its low bioavailability, and its limitations for children, which represent the major group of schistosomiasis patients.

Therefore, the authors should critically discuss this point in their Discussion chapter and should mention that \"analogs with varied efficacy, and potentially improved PK/PD\" based on the ergotamine core are needed to develop a lead that may have the potential to become an effective and safe drug.

10.7554/eLife.35755.026

Author response

> Essential revisions:
>
> 1\) Ergotamine is an alkaloid that shares structural similarity with neurotransmitters like dopamine. Acting as an agonist, this drug leads to vasoconstriction and is mainly prescribed for patients suffering from migraines. However, contraindications comprise among others hepatic disease, pregnancy, and the age of patients -- such as preschoolers. Since schistosomiasis mainly affects children, including preschoolers, and since it is also a hepatic disease, how safe or how problematic could this drug be for a patient?
>
> According to the Mayo Clinic recommendations (last update: March 01, 2017), 1 -- 2 mg are recommended for adults. In case no side effects occur, a second and even a third dose can be taken; however, the doses should be taken at least 30 minutes apart, and should not exceed 3 mg per day. Ergotamine should not be taken by very young children (\< 6 years). And from 6 years on, or older, 1 mg is recommended with a maximum of 3 mg a day along with the restriction that this drug should not be taken by children more often than 2 times a week, at least five days apart. Against the background of these facts and the animal data from this study (60 mg/kg twice daily for one week in the mouse model), the low bioavailability in human (2%, when given as tablet; PMCID: PMC1428366), and the short half time of 2 - -- 3 hours (https://druginfo.nlm.nih.gov/drugportal/rn/113-15-5), how realistic are the chances for ergotamine to become a drug repurposed for schistosomiasis?
>
> The potential problems that may arise with the repurposing of this drug and the extensive clinical testing in the context of treatment for schistosomiasis should be addressed in the Discussion.

We acknowledge the side effect profile of ergotamine and agree in the absence of preclinical data that speculation upon the human repurposing potential of ergotamine as a treatment is premature. Backing up, we believe our contribution in the context of academic drug-discovery is validation of new parasite targets and the discovery of new treatment strategies (drugs to engage both parasite and host responses, rather than just parasite-selective ligands), and would rather highlight our findings with ergotamine in this context. We have therefore removed previous text speculating on the repurposing potential of ergotamine throughout the manuscript text. Additionally, we note: (i) our SAR studies (Figure 3) underscore the potential for manipulation of the core ergot alkaloid pharmacophore to develop analogs with varied efficacy, and potentially improved PK/PD, (ii) treatment of parasitic diseases with a single bolus dose of drug may provide more flexibility than dosing parameters established on the basis of cumulative side effects from repeated drug dosing.

> 2\) The antiparasitic effect of ergotamine was accompanied by a marked apparent improvement in the pathological effects of infection on the host. The observed reduction in liver and spleen size and the improvement in liver morphology was found to correlate with an ergotamine-specific effect on hepatic stellate cells, and hence on liver fibrosis. A marked reduction in granuloma size and liver fibrosis is seen in congenitally athymic mice. However, in the case of S. mansoni infection, this leads to increased mortality and fewer eggs passed into the feces (Cheever et al., Am J Trop Med Hyg, 1993, 48:496-503). Byram and von Lichtenberg (Am J Trop Med Hyg, 1977, 26:944-56) suggested that the deficient granuloma formation led to failure to sequester toxic egg products, resulting in hepatocellular damage. Although smaller, the livers of ergotamine-treated, infected mice do not seem normal (Figure 5D) and have a darker color, even than control infected or PZQ-treated mice. Further, the picrosirius red-stained histological sections (Figure 5G) could be complemented with other staining methods to determine whether any hepatocyte necrosis is visible. It is important to show that the ergotamine effect on the host response is really beneficial.

We agree completely with these comments highlighting the multifaceted role of immune response to schistosome infection. As the reviewers point out, the granuloma may serve beneficial functions sequestering toxic egg components in the liver and facilitating egg transport across the intestinal mucosa for fecal excretion. If ergotamine treatment were to have deleterious effects, mimicking the scenario with T-cell deficient mice, we would expect to observe hepatocyte microvesicular steatosis and eggs accruing in the intestine (Doenhoff et al., 1986).

In the revised manuscript we have therefore expanded our histological analyses of control and drug-treated livers as suggested (Figure 6G, new text in the third paragraph of the subsection "In vivo efficacy of ergotamine", new Figure 6---figure supplement 2 and 4). We agree that the gross appearance of ergotamine-treated livers is not identical to uninfected livers, but the expanded histology, taken together with the RNA-seq data, indicate that they do much more closely resemble the uninfected state than PZQ-treated samples. These data show that ergotamine treatment results in decreased liver collagen staining, decreased elastin staining, decreased lipid loss and no elevation in caspase activation relative to both infected and PZQ-treated samples (Figure 6G, Figure 6---figure supplement 2). As the reviewers note, impairing granuloma formation could have deleterious effects. However, histology does not reveal hepatocyte damage or obvious microvesicular steatosis in the livers of ergotamine treated mice that exceeds that already present in control infections (Figure 6---figure supplement 4). However, it is the case that all infected livers -- from DMSO, ergotamine and praziquantel treated mice -- exhibit pathology such as increased white blood cells and occasional slight "foaminess" within hepatocytes. Our proposed model of ergotamine inhibition of pro-fibrotic HSC activation would not necessarily replicate models of ablated host T-cell response, which show blockage of egg passage across the intestinal barrier. We did not find that ergotamine treatment resulted in an accrual of intestinal eggs (Figure 6C), but we also cannot state that this is due to functional immune-meditated transport since it likely largely reflects impaired egg production due to decreased worm burden (Figure 6B) and impaired egg development (Figure 6---figure supplement 1). These data, as well as the increased survival of ergotamine-treated animals, do not indicate that host pathology is worsened with ergotamine treatment. Figure 6 has been expanded and two additional figure supplements (Figure 6---figure supplements 2 and 4) have been added to reflect the additional histology performed. New text discussing these data has also been added (in the aforementioned subsection and subsection "Action on host", second paragraph).

*3) Do these compounds (e.g., ergotamine) have activity against other schistosome stages (schistosomules, juveniles). Those experiments could be done* ex vivo *for a start, and subsequently* in vivo*. This issue is an important one, as juvenile worms (2-4 weeks p.i.) are refractory to PZQ. The issue should at least be discussed. Also do these compounds have activity in motility assays (or, even better,* in vivo*) against other species of schistosomes? Based on the data in Figure 3, one would expect they would, but it would be nice to know.*

We now provide both ex vivo and in vivo data to address this point in the revised manuscript. Figure 6---figure supplement 3 shows that ergotamine and 5-HT stimulate movement of juvenile worms ex vivo (Figure 6---figure supplement 3A and B). However in vivo, ergotamine -- like PZQ -- was ineffective at clearing infections (Figure 6---figure supplement 3C). Artemether was used as a positive control. These data suggest refractoriness to ergotamine at the juvenile stage of infection is not due to a lack of effect on the worms themselves. New text discussing these data has also been added (subsection "In vivo efficacy of ergotamine", fourth paragraph).

> 4\) Why is mouse survival lower in ergotamine-treated than in PZQ-treated infected mice despite the ameliorating effects of ergotamine on pathology.

Our in vivo work (Figure 6A) represents analysis of a single window of treatment (day 42-49) on survival over a subsequent 8 week period (to day 105). We expect that the remaining worm burden in mice sacrificed after 7 weeks reinitiates pathology over the subsequent monitoring period to cause the small extent of observed mortality.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed by editing the text before acceptance, as outlined below:
>
> In their revised version, Chan et al. addressed a number of points raised by the reviewers.
>
> With respect to my former comment that: \"contraindications comprise among others hepatic disease, pregnancy, and the age of patients -- such as preschoolers. Since schistosomiasis mainly affects children, including preschoolers, and since it is also a hepatic disease, how safe or how problematic could this drug be for a patient?\" the authors responded that they \"acknowledge the side effect profile of ergotamine and agree in the absence of preclinical data that speculation upon the human repurposing potential of ergotamine as a treatment is premature. \[...\] Additionally, we note: (i) our SAR studies (Figure 3) underscore the potential for manipulation of the core ergot alkaloid pharmacophore to develop analogs with varied efficacy, and potentially improved PK/PD, (ii) treatment of parasitic diseases with a single bolus dose of drug may provide more flexibility than dosing parameters established on the basis of cumulative side effects from repeated drug dosing.\"
>
> In their marked version, however, it is not possible to follow these deletions since appropriate positions have not been marked as deleted within the text. Please indicate the \"removed previous text speculating\" clearly. Furthermore, I miss comments within the manuscript with respect to \"the potential for manipulation of the core ergot alkaloid pharmacophore to develop analogs with varied efficacy, and potentially improved PK/PD\". The chapter \"Structural determinates of activity at schistosome 5-HTRs\" ends with \" ergotamine (compound \'1) as the most potent, full agonist and 2-Bromo-LSD (compound \'20\') as the most potent antagonist for further evaluation.\" Unfortunately, also the Discussion fails to discuss this point critically. Instead, the Discussion ends with the conclusion that \"\[\...\] ergotamine is fortuitously suited to engage pathways in both host and parasite that are simultaneously deleterious to the blood fluke but beneficial to the infected host in terms of worm clearance and mitigation of damage caused by eggs\" This is suggestive for its repurposing potential, even without mentioning this word.

Side effects of ergotamine:We apologize that the resubmitted version did not show deleted text in the comments pane, only the changed text, from the prior version. Sections deleted based on comments in the prior review report are now shown. We have added a new section in the Discussion (new text, subsection "Action on host", third paragraph) which highlights the challenges of ergotamine as a lead compound. This new text makes clear the challenges with ergotamine as a repurposing candidate itself, which is not the intended implication of this study: ergotamine simply illustrates the potential benefit of coalescing beneficial host actions (on stellate cells) with deleterious antiparasitic activity in eliminating worms and mitigating their pathological effects. Ergotamine certainly has many additional side effects in healthy patients, which are fully acknowledged in the reviewers' report and manuscript.

> In the Abstract the authors mention that \"Conventional approaches for antiparasitic drug discovery center upon discovering selective agents that adversely impact parasites with minimal host side effects\". Especially the latter seems not applicable against the background of all known contradictions of ergotamine, its low bioavailability, and its limitations for children, which represent the major group of schistosomiasis patients.
>
> Therefore, the authors should critically discuss this point in their Discussion chapter and should mention that \"analogs with varied efficacy, and potentially improved PK/PD\" based on the ergotamine core are needed to develop a lead that may have the potential to become an effective and safe drug.

The final sentence of the Abstract has now been changed to underscore that ergotamine exemplifies a novel *strategy* for anthelmintic drug design by representing an agent that combines beneficial effects on host with deleterious actions on the parasite. The adverse side effects of ergotamine are explicitly addressed in new Discussion (subsection "Action on host") that highlight predicted problems (the negative side effects observed with the beneficial host effects, low bioavailability, pediatric dosage).
